186. Feasibility of Concomitant Radio-Chemotherapy in High Risk Endometrial Cancer
(In Coll. G.Mangili, S.Beatrice, F.Olivari, F.Zanetto, M.Carnelli, G.Aletti)
Internat J Gynecol Cancer. Vol. 7, Suppl. 1, 82, 1999
Summary: In patients with high risk endometrial cancer who have received post-operative Radio-Therapy (RT), most relapses have been observed to develop out of the irradiation field. Paclitaxel (P) has proven to be effective in the treatment of metastatic endometrial cancer. It has shown exellent radiosensitzing activity. Nine patients with high risk endometrial cancer received 60 mg/m2 of P given as a single dose weekly for 5 weeks with concurrent RT (45-50 Gy). Three weekly additional courses of P (80 mg/m2) were subministered at the end of RT. This regimen has shown to be well tollerated.
